88
Participants
Start Date
August 10, 2023
Primary Completion Date
May 7, 2025
Study Completion Date
June 2, 2025
EO-3021
Anti-Claudin 18.2 antibody drug conjugate
Ramucirumab (CYRAMZA®)
VEGFR2 inhibitor
Dostarlimab
anti-PD-1 antibody
Memorial Sloan Kettering Cancer Center, New York
Georgetown University, Washington D.C.
Johns Hopkins University - Sibley Memorial Hospital, Washington D.C.
Atrium Health/Wake Forest University, Charlotte
Mayo Clinic, Jacksonville
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Sarah Cannon Research Institute, Nashville
Henry Ford Cancer, Detroit
START Midwest, Grand Rapids
UW Carbone Cancer Center - Cancer Connect, Madison
Mayo Clinic, Rochester
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center, Houston
Mayo Clinic, Phoenix
City of Hope, Duarte
Yale - Smilow Cancer Hospital, New Haven
National Cancer Center Hospital East, Kashiwa-shi
National Cancer Center Hospital, Chuo Ku
Samsung Medical Center, Seoul
Yonsei University, Seoul
Lead Sponsor
Collaborators (2)
Eli Lilly and Company
INDUSTRY
GlaxoSmithKline
INDUSTRY
CSPC Pharmaceutical Group Limited
INDUSTRY
Elevation Oncology
INDUSTRY